Article Text

Download PDFPDF
Galantamine improved cognition and global functioning in vascular dementia or Alzheimer’s disease with cerebrovascular disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In patients with probable vascular dementia or Alzheimer’s disease (AD) with cerebrovascular disease, is galantamine more effective than placebo for improving cognitive ability and global functioning?


6 month randomised (unclear allocation concealment*), blinded (clinicians and patients),* placebo-controlled trial.


Canada, Denmark, Finland, France, Germany, Ireland, Israel, The Netherlands, Poland, and the UK.


592 patients (mean age 75 y, 53% men) who met clinical criteria for probable vascular dementia or possible AD with radiological evidence of cerebrovascular disease. Additional inclusion criteria included a score of 10 to 25 on the Mini-Mental State Examination and ≥12 on the Alzheimer Disease Assessment Scale Cognitive subscale (ADAS-COG). Exclusion criteria included evidence of neurodegenerative disorders other than AD that might cause or contribute to dementia, and cognitive …

View Full Text


  • Source of funding: not stated.

  • For correspondence: Dr T Erkinjuntti, Helsinki University Central Hospital, Helsinki, Finland. Email timo.erkinjuntti{at}

  • * See glossary.